Characteristics of the study group before treatment
| Feature . | No. (% of 75 patients) . |
|---|---|
| Age, y | |
| Median | 53 |
| 60 or older | 27 (36) |
| Splenomegaly > 5 cm bcm | 28/68 (41) |
| Hemoglobin < 10 g/dL | 38 (51) |
| White blood cell count > 50 × 109/L | 21 (28) |
| Platelet count < 100 × 109/L | 41 (55) |
| Other chromosomal abnormalities | 43/71 (61) |
| Peripheral blasts > 30% | 52 (69) |
| Marrow blasts > 50% | 40 (53) |
| Blast morphology | |
| Lymphoid | 10 (13) |
| Myeloid, undifferentiated | 65 (87) |
| Time from diagnosis to blastic phase, mo | |
| < 12 | 17 (23) |
| 12-35 | 20 (27) |
| ≥ 36 | 38 (51) |
| Blastic phase salvage | |
| First | 50 (67) |
| ≥ Second | 25 (33) |
| Feature . | No. (% of 75 patients) . |
|---|---|
| Age, y | |
| Median | 53 |
| 60 or older | 27 (36) |
| Splenomegaly > 5 cm bcm | 28/68 (41) |
| Hemoglobin < 10 g/dL | 38 (51) |
| White blood cell count > 50 × 109/L | 21 (28) |
| Platelet count < 100 × 109/L | 41 (55) |
| Other chromosomal abnormalities | 43/71 (61) |
| Peripheral blasts > 30% | 52 (69) |
| Marrow blasts > 50% | 40 (53) |
| Blast morphology | |
| Lymphoid | 10 (13) |
| Myeloid, undifferentiated | 65 (87) |
| Time from diagnosis to blastic phase, mo | |
| < 12 | 17 (23) |
| 12-35 | 20 (27) |
| ≥ 36 | 38 (51) |
| Blastic phase salvage | |
| First | 50 (67) |
| ≥ Second | 25 (33) |
bcm indicates below costal margin.